Matinas Biopharma Hl (MTNB) 0.7900 $MTNB
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
GlobeNewswire - Fri Sep 18, 2:06PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented data from a preclinical study demonstrating tissue targeting and penetration potential of MAT2203, an orally-administered, encochleated formulation of the broad spectrum antifungal medication amphotericin B (AmB).
Matinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board
GlobeNewswire - Thu Sep 17, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that it has appointed Peter G. Pappas, M.D., FACP, to its Scientific Advisory Board (SAB).
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
GlobeNewswire - Tue Sep 01, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that Raphael J. Mannino, Ph.D., has been appointed Senior Vice President and Chief Technology Officer effective Sept. 1, 2015.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status.
Matinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
GlobeNewswire - Mon Jul 27, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that preclinical data on encochleated atovaquone (CATQ) will be presented at IDWeek 2015 Oct. 7-11 in San Diego.
This is Why the Orphan Drug Space is Easing Worries About Broader Biotech Bubble
ACCESSWIRE - Thu Jul 23, 7:00AM CDT
CORAL GABLES, FL / ACCESSWIRE / July 23, 2015 / Since July 2010, the iShares Nasdaq Biotechnology ETF (IBB) has gained more than 370%, rising from $77 on July 12, 2010 to June 2015 highs of $377 a share. A number of leading news media outlets are starting to report that we are in the midst of a biotech bubble, and that this bubble looks set to burst before the end of the year. This is not to say, however, that there are not opportunities in the space going forward.
RTRX: 20.22 (+1.07), LPCN: 12.74 (+0.23), LBIO: 6.48 (+0.03)
Matinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
GlobeNewswire - Thu Jul 23, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that it appointed David S. Perlin, Ph.D., to its infectious diseases Scientific Advisory Board (SAB).
Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
GlobeNewswire - Tue Jul 14, 6:35AM CDT
Data demonstrating rapid tissue penetration in animal studies of oral encochleated Amphotericin B in systemic candidiasis to be presented on Sept. 18
Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
GlobeNewswire - Tue Jul 07, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company"
, a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12 Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA.
Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
GlobeNewswire - Mon Jun 15, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 levels.
Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
GlobeNewswire - Wed Jun 10, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA.
Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
GlobeNewswire - Thu Jun 04, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting additional data from the MAT9001 head-to-head comparative pharmacokinetic and pharmacodynamic (PK/PD) study versus Vascepa (icosapent ethyl) at the National Lipid Association (NLA) Scientific Sessions being held June 11-14, 2015, in Chicago, IL.
Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 32.23 (-0.16), AMRN: 2.08 (+0.04), GSK: 40.22 (+0.06)
Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT
AMRN: 2.08 (+0.04)
Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
GlobeNewswire - Mon Jun 01, 7:00AM CDT
- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -
Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
GlobeNewswire - Thu May 28, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA.
Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
GlobeNewswire - Tue May 26, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
GlobeNewswire - Fri Sep 18, 2:06PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented data from a preclinical study demonstrating tissue targeting and penetration potential of MAT2203, an orally-administered, encochleated formulation of the broad spectrum antifungal medication amphotericin B (AmB).
Matinas BioPharma Appoints International Expert and Thought Leader on Invasive Fungal Infections Peter G. Pappas, M.D., FACP, to Scientific Advisory Board
GlobeNewswire - Thu Sep 17, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that it has appointed Peter G. Pappas, M.D., FACP, to its Scientific Advisory Board (SAB).
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
GlobeNewswire - Tue Sep 01, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that Raphael J. Mannino, Ph.D., has been appointed Senior Vice President and Chief Technology Officer effective Sept. 1, 2015.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by U.S. FDA
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status.
Matinas BioPharma Announces Abstract on Pharmacokinetics and Efficacy of Encochleated Atovaquone in Murine Model of Pneumocystis Accepted for Oral Presentation at IDWeek 2015
GlobeNewswire - Mon Jul 27, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that preclinical data on encochleated atovaquone (CATQ) will be presented at IDWeek 2015 Oct. 7-11 in San Diego.
This is Why the Orphan Drug Space is Easing Worries About Broader Biotech Bubble
ACCESSWIRE - Thu Jul 23, 7:00AM CDT
CORAL GABLES, FL / ACCESSWIRE / July 23, 2015 / Since July 2010, the iShares Nasdaq Biotechnology ETF (IBB) has gained more than 370%, rising from $77 on July 12, 2010 to June 2015 highs of $377 a share. A number of leading news media outlets are starting to report that we are in the midst of a biotech bubble, and that this bubble looks set to burst before the end of the year. This is not to say, however, that there are not opportunities in the space going forward.
RTRX: 20.22 (+1.07), LPCN: 12.74 (+0.23), LBIO: 6.48 (+0.03)
Matinas BioPharma Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
GlobeNewswire - Thu Jul 23, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today announced that it appointed David S. Perlin, Ph.D., to its infectious diseases Scientific Advisory Board (SAB).
Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
GlobeNewswire - Tue Jul 14, 6:35AM CDT
Data demonstrating rapid tissue penetration in animal studies of oral encochleated Amphotericin B in systemic candidiasis to be presented on Sept. 18
Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
GlobeNewswire - Tue Jul 07, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) ("Matinas BioPharma" or the "Company"
, a clinical-stage biopharmaceutical company, today announced that it will be presenting at the 12 Anti-Infectives Partnering and Deal Making Conference being held July 9-10, 2015, in Boston, MA. Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
GlobeNewswire - Mon Jun 15, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 levels.
Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
GlobeNewswire - Wed Jun 10, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the BIO International Convention being held June 15-18, 2015, in Philadelphia, PA. Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
GlobeNewswire - Thu Jun 04, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting additional data from the MAT9001 head-to-head comparative pharmacokinetic and pharmacodynamic (PK/PD) study versus Vascepa (icosapent ethyl) at the National Lipid Association (NLA) Scientific Sessions being held June 11-14, 2015, in Chicago, IL. Matinas and Amarin's Destinies are Linked as MAT9001 Outshines Vascepa
ACCESSWIRE - Wed Jun 03, 2:42PM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / It was April 2011 and Amarin (NASDAQ: AMRN) shareholders were flying high. As data came in for the company's pivotal phase 3 trial for Vascepa, an omega-3 fatty acid drug trialed to reduce very high triglycerides in the blood, shares went from $8.75 to a high of $19.50 just over a month later. But as excitement wore off, shares had collapsed down to pre-data-release levels by December.
AZN: 32.23 (-0.16), AMRN: 2.08 (+0.04), GSK: 40.22 (+0.06)
Matinas MAT9001 Beats Vascepa In Head-To-Head Trial
Jason Napodano, CFA - at Seeking Alpha - Mon Jun 01, 1:28PM CDT
AMRN: 2.08 (+0.04)
Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
GlobeNewswire - Mon Jun 01, 7:00AM CDT
- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -
Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
GlobeNewswire - Thu May 28, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of targeted therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the LD Micro Invitational being held June 1-3, 2015, at the Luxe Sunset Boulevard, Los Angeles, CA. Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
GlobeNewswire - Tue May 26, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development of lipid-based prescription therapeutics for the treatment of infectious diseases, today announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY. 
